Abstract Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and
effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a …

In 2022, a global outbreak of Mpox (formerly monkeypox) occurred in various countries
across Europe and America and rapidly spread to more than 100 countries and regions. The …

Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

COVID-19 in immunocompromised hosts has emerged as a difficult therapeutic
management problem. Immunocompromised hosts mount weak responses to SARS-CoV-2 …

Objective To examine the association of COVID-19 convalescent plasma transfusion with
mortality and the differences between subgroups in hospitalized patients with COVID-19 …

Introduction When the COVID-19 pandemic struck no specific therapies were available and
many turned to COVID-19 convalescent plasma (CCP), a form of antibody therapy. The …

Background: While passive immunotherapy has been considered beneficial for patients with
severe respiratory viral infections, the treatment of COVID-19 cases with convalescent …

Background Plasma collected from recovered COVID-19 patients (COVID-19 convalescent
plasma, CCP) was the first antibody-based therapy employed to fight the COVID-19 …

Extensive research in countries with high sociodemographic indices (SDIs) to date has
shown that coronavirus disease 2019 (COVID-19) may be directly associated with more …